ATTROGY® (diflunisal) is approved by the European Medicines Agency (EMA) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. Further information can be found here: EMA Product Information

This product has not been approved by the U.S. Food and Drug Administration (FDA). Diflunisal has been granted orphan drug designation in the US for the treatment of transthyretin-mediated amyloidosis.